Merck & Company (MRK) Stock Forecast & Price Target

Compare

14,702 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

MRK Analyst Ratings

Moderate Buy

12 Buy

7 Hold

0 Sell

Based on 19 analysts giving stock ratings to

Merck

& Company

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

MRK Stock 12 Month Forecast

Average Price Target

$122.95

▲(6.14% Upside)

Based on 19 Wall Street analysts offering 12 month price targets for Merck & Company in the last 3 months. The average price target is $122.95 with a high forecast of $139.00 and a low forecast of $95.00. The average price target represents a 6.14% change from the last price of $115.84.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"73":"$73","140":"$140","89.75":"$89.8","106.5":"$106.5","123.25":"$123.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":139,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$139.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":122.94736842105263,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$122.95</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":95,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$95.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[73,89.75,106.5,123.25,140],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,113.37,115.34153846153846,117.31307692307692,119.28461538461539,121.25615384615385,123.22769230769231,125.19923076923077,127.17076923076924,129.1423076923077,131.11384615384617,133.0853846153846,135.05692307692308,137.02846153846153,{"y":139,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,113.37,114.10672064777329,114.84344129554657,115.58016194331984,116.31688259109312,117.0536032388664,117.79032388663968,118.52704453441295,119.26376518218623,120.00048582995952,120.7372064777328,121.47392712550607,122.21064777327935,{"y":122.94736842105263,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,113.37,111.95692307692308,110.54384615384616,109.13076923076923,107.71769230769232,106.30461538461539,104.89153846153846,103.47846153846154,102.06538461538462,100.65230769230769,99.23923076923077,97.82615384615384,96.41307692307693,{"y":95,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":95.24,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.91,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.69,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.94,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.12,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.32,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.85,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":83.93,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.37,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.25,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.97,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":105.26,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.37,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$139.00

Average Price Target$122.95

Lowest Price Target$95.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Jason Gerberry

Bank of America Securities

$124→$132

Buy

13.95%

Upside

Reiterated

02/04/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Minerva Neurosciences (NASDAQ: NERV), Gossamer Bio (NASDAQ: GOSS) and Merck & Company (NYSE: MRK)

Terence Flynn

Morgan Stanley

$101→$109

Hold

-5.90%

Downside

Reiterated

02/04/26

Hold Steady on Merck: Solid Keytruda Base but Pipeline Uncertainty Keeps Upside Limited

Mohit Bansal

Wells Fargo

$125→$135

Buy

16.54%

Upside

Reiterated

02/04/26

Merck price target raised to $135 from $125 at Wells FargoMerck price target raised to $135 from $125 at Wells Fargo

Geoff Meacham

Citi

$115→$120

Hold

3.59%

Upside

Reiterated

02/04/26

Merck price target raised to $120 from $115 at CitiMerck price target raised to $120 from $115 at Citi

Courtney Breen

Bernstein

$95→$100

Hold

-13.67%

Downside

Reiterated

02/04/26

Merck price target raised to $100 from $95 at BernsteinMerck price target raised to $100 from $95 at Bernstein

Asad Haider

Goldman Sachs

$120→$133

Buy

14.81%

Upside

Reiterated

02/04/26

Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN), Pfizer (NYSE: PFE) and Merck & Company (NYSE: MRK)

Carter Gould

Cantor Fitzgerald

$116→$120

Hold

3.59%

Upside

Reiterated

02/04/26

Analysts Offer Insights on Healthcare Companies: McKesson (NYSE: MCK), GE Healthcare Technologies Inc (NASDAQ: GEHC) and Merck & Company (NYSE: MRK)

Louise Chen

Scotiabank

$120→$136

Buy

17.40%

Upside

Reiterated

02/04/26

Merck price target raised to $136 from $120 at ScotiabankMerck price target raised to $136 from $120 at Scotiabank

Evan Seigerman

BMO Capital

$135

Buy

16.54%

Upside

Upgraded

02/03/26

BMO Capital Reaffirms Their Buy Rating on Merck & Company (MRK)

Nico Chen

DBS

$130

Buy

12.22%

Upside

Reiterated

01/28/26

Analysts Offer Insights on Healthcare Companies: Merck & Company (NYSE: MRK) and UnitedHealth (NYSE: UNH)

Steve Scala

TD Cowen

$100→$120

Hold

3.59%

Upside

Reiterated

01/20/26

Merck: Solid Near-Term Earnings but Muted Post-LOE Growth Keeps Rating at Hold

Alexandria Hammond

Wolfe Research

$135

Buy

16.54%

Upside

Upgraded

01/08/26

Merck upgraded to Outperform from Peer Perform at Wolfe ResearchMerck upgraded to Outperform from Peer Perform at Wolfe Research

Michael Yee

UBS

$105→$130

Buy

12.22%

Upside

Reiterated

01/07/26

Merck price target raised to $130 from $105 at UBSMerck price target raised to $130 from $105 at UBS

Luisa Hector

Berenberg Bank

$95

Hold

-17.99%

Downside

Reiterated

01/06/26

Analysts Are Neutral on Top Healthcare Stocks: Merck & Company (MRK), Eli Lilly & Co (LLY)

Tycho Peterson

Jefferies

$139

Buy

19.99%

Upside

Reiterated

12/19/25

Jefferies Keeps Their Buy Rating on Merck & Company (MRK)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Jason Gerberry

Bank of America Securities

$124→$132

Buy

13.95%

Upside

Reiterated

02/04/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Minerva Neurosciences (NASDAQ: NERV), Gossamer Bio (NASDAQ: GOSS) and Merck & Company (NYSE: MRK)

Terence Flynn

Morgan Stanley

$101→$109

Hold

-5.90%

Downside

Reiterated

02/04/26

Hold Steady on Merck: Solid Keytruda Base but Pipeline Uncertainty Keeps Upside Limited

Mohit Bansal

Wells Fargo

$125→$135

Buy

16.54%

Upside

Reiterated

02/04/26

Merck price target raised to $135 from $125 at Wells FargoMerck price target raised to $135 from $125 at Wells Fargo

Geoff Meacham

Citi

$115→$120

Hold

3.59%

Upside

Reiterated

02/04/26

Merck price target raised to $120 from $115 at CitiMerck price target raised to $120 from $115 at Citi

Courtney Breen

Bernstein

$95→$100

Hold

-13.67%

Downside

Reiterated

02/04/26

Merck price target raised to $100 from $95 at BernsteinMerck price target raised to $100 from $95 at Bernstein

Asad Haider

Goldman Sachs

$120→$133

Buy

14.81%

Upside

Reiterated

02/04/26

Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN), Pfizer (NYSE: PFE) and Merck & Company (NYSE: MRK)

Carter Gould

Cantor Fitzgerald

$116→$120

Hold

3.59%

Upside

Reiterated

02/04/26

Analysts Offer Insights on Healthcare Companies: McKesson (NYSE: MCK), GE Healthcare Technologies Inc (NASDAQ: GEHC) and Merck & Company (NYSE: MRK)

Louise Chen

Scotiabank

$120→$136

Buy

17.40%

Upside

Reiterated

02/04/26

Merck price target raised to $136 from $120 at ScotiabankMerck price target raised to $136 from $120 at Scotiabank

Evan Seigerman

BMO Capital

$135

Buy

16.54%

Upside

Upgraded

02/03/26

BMO Capital Reaffirms Their Buy Rating on Merck & Company (MRK)

Nico Chen

DBS

$130

Buy

12.22%

Upside

Reiterated

01/28/26

Analysts Offer Insights on Healthcare Companies: Merck & Company (NYSE: MRK) and UnitedHealth (NYSE: UNH)

Steve Scala

TD Cowen

$100→$120

Hold

3.59%

Upside

Reiterated

01/20/26

Merck: Solid Near-Term Earnings but Muted Post-LOE Growth Keeps Rating at Hold

Alexandria Hammond

Wolfe Research

$135

Buy

16.54%

Upside

Upgraded

01/08/26

Merck upgraded to Outperform from Peer Perform at Wolfe ResearchMerck upgraded to Outperform from Peer Perform at Wolfe Research

Michael Yee

UBS

$105→$130

Buy

12.22%

Upside

Reiterated

01/07/26

Merck price target raised to $130 from $105 at UBSMerck price target raised to $130 from $105 at UBS

Luisa Hector

Berenberg Bank

$95

Hold

-17.99%

Downside

Reiterated

01/06/26

Analysts Are Neutral on Top Healthcare Stocks: Merck & Company (MRK), Eli Lilly & Co (LLY)

Tycho Peterson

Jefferies

$139

Buy

19.99%

Upside

Reiterated

12/19/25

Jefferies Keeps Their Buy Rating on Merck & Company (MRK)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Merck & Company

3 Months

xxx

Success Rate

19/27 ratings generated profit

Average Return

+4.00%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 70.37% of your transactions generating a profit, with an average return of +4.00% per trade.

1 Year

Daina GrayboschLeerink Partners

Success Rate

36/52 ratings generated profit

Average Return

+11.45%

a rating ―

Copying Daina Graybosch's trades and holding each position for 1 Year would result in 69.23% of your transactions generating a profit, with an average return of +11.45% per trade.

2 Years

xxx

Success Rate

19/20 ratings generated profit

Average Return

+21.60%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 95.00% of your transactions generating a profit, with an average return of +21.60% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MRK Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, MRK has received 26 Buy Ratings, 15 Hold Ratings, and 0 Sell Ratings. MRK average Analyst price target in the past 3 months is 122.95.

Each month's total comprises the sum of three months' worth of ratings.

MRK Financial Forecast

MRK Earnings Forecast

Next quarter’s earnings estimate for MRK is -$1.51 with a range of -$1.72 to -$1.36. The previous quarter’s EPS was $2.04. MRK beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year MRK has Performed in-line its overall industry.

MRK Sales Forecast

Next quarter’s sales forecast for MRK is $15.97B with a range of $15.11B to $16.54B. The previous quarter’s sales results were $16.40B. MRK beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year MRK has Performed in-line its overall industry.

MRK Stock Forecast FAQ

What is MRK’s average 12-month price target, according to analysts?

Based on analyst ratings, Merck & Company’s 12-month average price target is 122.95.

What is MRK’s upside potential, based on the analysts’ average price target?

Merck & Company has 6.14% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is MRK a Buy, Sell or Hold?

Merck & Company has a consensus rating of Moderate Buy which is based on 12 buy ratings, 7 hold ratings and 0 sell ratings.

What is Merck & Company’s price target?

The average price target for Merck & Company is 122.95. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $139.00 ,the lowest forecast is $95.00. The average price target represents 6.14% Increase from the current price of $115.84.

What do analysts say about Merck & Company?

Merck & Company’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 19 Wall Streets Analysts.

How can I buy shares of MRK?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Merck & Company (MRK) Stock Forecast & Price Target

MRK Analyst Ratings

MRK Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Merck & Company

MRK Analyst Recommendation Trends

MRK Financial Forecast

MRK Earnings Forecast

MRK Sales Forecast

MRK Stock Forecast FAQ

Detailed List of Analyst Forecasts